<div>
  <ul>
    <li>
      <p>
        London-based clinical trial startup uMotif raised USD 25.5 million in funding from Athyrium Capital. This follows a GBP 5 million (USD 6.6 million) Series A funding round in September 2020, led by existing investor AlbionVC.
      </p>
    </li>
    <li>
      <p>
        The proceeds are to be utilized for scaling and geographic expansion of its platform from the 30 countries that currently use it. Additionally, the company plans to grow its headcount in North America, including sales and marketing resources.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst Quicktake: </b>
        The investment should strengthen uMotif both financially and in terms of potential partnerships and sales reach in the North American market.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.mobihealthnews.com/news/clinical-trial-tech-company-umotif-scores-255m-continue-international-expansion">
      Mobi Health News
    </a>
  </p>
  <p>
    <a href="https://www.prnewswire.co.uk/news-releases/umotif-the-patient-first-data-capture-and-decentralized-clinical-trials-platform-announces-25-5m-of-new-investment-from-a-fund-managed-by-athyrium-capital-management-815315729.html">
      Newswire
    </a>
  </p>
  <p>
    <a href="https://umotif.com/news/25-5mofnewinvestmentfromafundmanagedbyathyriumcapitalmanagement/">
      uMotif
    </a>
  </p>
</div>


Clinical Trial Technology

uMotif raises USD 25.5 million from Athyrium Capital

PROMINENT_CATEGORY

<div>
 <p>Flatiron Health, a company specializing in real-world data for cancer care, and the National Comprehensive Cancer Network (NCCN), an alliance of leading cancer centers, will continue their partnership aimed at improving cancer care and enhancing research. The collaboration primarily focuses on optimizing the use of real-world data for research purposes.</p>
 <p>The partnership will also focus on providing cancer centers across the nation with access to Flatiron's high-quality data for performance benchmarking and improvements. Both organizations will work together towards enhancing the quality of care through the development of new metrics and benchmarks to assess and measure the standard of cancer care provided.&nbsp;</p>
</div>

Flatiron Health renews collaboration with NCCN to improve cancer care

INCUMBENTS_PRESENT

<div>
 <p>IQVIA, an analytics, research and technology services provider, has extended its partnership with global cloud computing company Salesforce to foster the development of Salesforce's Life Sciences Cloud, which is a customer engagement platform for the global life sciences industry.</p>
 <p>IQVIA will make use of their Orchestrated Customer Engagement (OCE) platform that includes data and analytics capabilities alongside Salesforce's Customer Relationship Management (CRM) solutions to create a comprehensive engagement platform for life science companies. IQVIA plans to license its engagement platform and related software to Salesforce to aid the platform’s development, with an expected launch date for Salesforce Life Sciences Cloud set for 2025.</p>
</div>

IQVIA expands partnership with Salesforce to develop customer engagement platform for life sciences

<div>
 
 <p>Manifold, an AI-powered clinical research management platform provider, has raised 15 million US dollars in a series A funding round. The round was led by TQ Ventures, with participation from several venture capital firms and individual investors, bringing the total funds raised by Manifold to nearly 23 million US dollars. The funds will be used to expand the company's market reach and invest in R&amp;D to enhance its platform's functionality.</p>
 
<p>Manifold offers AI-based clinical research platforms designed to simplify research operations, efficiently manage data, and provide valuable insights. The platforms support researchers throughout various phases of clinical studies, including the management of cohorts, the curation of clinical and multi-omic data, data analysis, and collaboration. Manifold provides two platforms: Observational Study and Biobank Core. The former digitalizes workflows, connects data silos, and enables secure collaboration, while the latter connects biospecimen data with clinical and genetic data for analysis, manages data, and facilitates communication with cohorts. Both use AI to automate and improve data analysis, making insight generation easier for researchers. As of April 2024, Manifold has partnered with institutions including the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the Winship Cancer Institute of Emory University.</p>

</div>

Manifold raises USD 15 million in Series A funding

<div>
 
 <p>Pi Health, a provider of site selection and clinical trial management platforms, has raised over USD 30 million in a Series A investment round. This round was co-led by AlleyCorp and Obvious Ventures and saw participation from other venture capital firms and oncology leaders.</p>
 <p>With the newly raised funds, Pi Health plans to extend its partnerships with international trial sites and life sciences corporations. Additionally, the funds will also support the development of Pi Health's proprietary Front-End Interoperable Capture Software (FICS).</p>
 <p>Founded in 2021, Pi Health is primarily focused on providing oncology-focused clinical trial technology. Its platform, the FICS, automates manual processes to ensure a faster and more efficient data collection process during patient care. The company offers two versions of its FICS platform - FICS HARMONY for site selection in clinical trials and FICS UNITY for overseeing and managing clinical trials. As of March 2024, Pi Health has established partnerships with oncology centers across the US, Brazil, Australia, and India.</p>
 
</div>

Pi Health raises over USD 30 million in Series A funding to expand network

<div>
 
 <p>Healthcare technology provider, Flatiron Health, has collaborated with the Medical University of South Carolina (MUSC) to offer its oncology-specific clinical decision support platform, Flatiron Assist, to MUSC's Hollings Cancer Center. </p>
 <p>The partnership will see Flatiron Assist being directly incorporated into MUSC’s electronic health records, providing crucial cancer care insights to assist physicians in making knowledgeable treatment decisions. As of March 2024, the platform has proven instrumental for over 700 oncologists in more than 90,000 treatment decisions and is predicted to standardize care across providers, thereby promising more efficient and equitable care for cancer patients.</p>
 
</div>

Flatiron Health partners with MUSC to improve cancer care with clinical decision support tool

<div>
 <p>Research management firm Medeloop has partnered with Quebec's Mila research center to incorporate AI into health research and accelerate clinical trials. Specific terms and financial details of the deal are yet unrevealed.</p>
 <p>Through the partnership, Medeloop's AI platform and Mila's machine learning researchers will be leveraged to expedite the clinical research process. The goal is to find patterns in medical data, optimize patient treatments, and enhance global healthcare.&nbsp;</p>
</div>

Medeloop partners with Mila to integrate AI into health research

<div>
 
 <p>Yendou, a Clinical Trial Tech provider, has raised EUR 1.2 million (USD 1.3 million) in a pre-seed funding round. The round was led by b2venture and included other venture capital companies, funds, and angel investors.</p>
 <p>The company plans to use the funds to expand its clinical operations automation platform. This expansion aims to cater to the growing needs of pharmaceutical and biotech companies.</p>
 <p>Based in Berlin and founded in 2023, Yendou provides life sciences companies with a clinical trial management technology solution. The platform streamlines clinical trial processes, reduces costs, and shortens timeframes. It also offers features such as site intelligence, Non-Disclosure Agreement (NDA) management, milestone acceleration, workflow automation, data analytics, and trial progress tracking. By February 2024, Yendou's platform was already in use by 1,200 clinicians in 46 countries.</p>
 
</div>

Yendou raises EUR 1.2 million in pre-seed funding

<div>
 
 <p>Power Life Sciences, a provider of a clinical trial recruitment platform, has raised USD 11.9 million in a Series A funding round. The round was co-led by Kin Ventures, Contrary, and Footwork, bringing the total investment in the company to approximately USD 30.8 million.</p>
 <p>The company plans to use the new funds to further develop its platform, offer more support to research teams, and contribute to a fairer clinical trial ecosystem.&nbsp;</p>
 <p>Established in 2021, Power Life Sciences offers a platform called Power that serves as a bridge between patients and researchers for clinical trials. The Power platform offers a sorting feature for users to find suitable clinical trials based on treatment areas, location, age restrictions, and participant proximity. The platform also offers straightforward summaries of the trials, helping patients understand them better and feel confident about their trial choices. Moreover, it allows participants to directly reach out to researchers for further trial details.</p>
 
</div>

Power Life Sciences raises USD 11.9 million in Series A funding

ANALYST_QUICK_TAKE

<div>
<p>Clinical research specialist, Science 37, has agreed to a USD 38 million merger deal with virtual care leader, eMed. The acquisition is an effort to boost Science 37's patient access, accelerate study enrollments and ensure long-term sustainability. The merger, subject to the majority of Science 37's shares being tendered, is set to be completed by Q1 2024. Upon completion, Science 37 will become a privately held company. eMed provides at-home healthcare testing and treatment programs for various conditions, paired with telehealth consultations and same-day medication delivery. </p>
</div> <p><b>Analyst QuickTake</b> : Science 37 initially went public via a Special Purpose Acquisition Company (SPAC) deal in October 2021 and was valued at more than USD 1 billion at the time. The company’s sharp drop in value is attributable to two main factors: Unrecognized revenue associated with backlogs and cancellations and the inability to secure contracts outside of the US. This transaction marks the second eMed has completed in a 12 month period, with its UK arm previously having <a href="https://sp-edge.com/updates/21451"> acquired Babylon Health’s </a> failing UK-based operations for an undisclosed sum.&nbsp;</p>

eMed acquires Science 37 for approximately USD 38 million

<div>
 
 <p>Sano Genetics, a firm offering a patient recruitment platform, has gathered USD 11.4 million in a funding round led by Plural, raising their total funding to USD 22 million. The firm plans to use the funding for product demand, AI integration, and expansion into new countries.</p>
 <p>The platform is already operational in the UK, the US, Australia, and Canada, connecting patients with pharmaceutical and biotech companies running clinical trials. Besides, the platform also aids in patient communication and provides support for genetic counseling.</p>
 
</div>

All Updates